Bristol-Myers Squibb (BMY) News
NYSE: BMYHealth CareBiotechnology: Pharmaceutical PreparationsUSD
59.12-0.46 (-0.77%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
BMY news summary
We found 37 recent headlines mentioning Bristol-Myers Squibb (BMY): 18 in the past week and 30 in the past 30 days, most often from Nasdaq, Seeking Alpha. For price context, BMY is down 0.77% at $59.12. The most recent story, "Bristol Myers Squibb vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?", was published by Nasdaq on Oct 8, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Bristol-Myers Squibb headlines
- Bristol Myers Squibb vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?Key PointsBristol Myers Squibb maintains a robust portfolio in oncology and hematology with a focus on specialized treatments.NasdaqBMY, PFE
- Marathon Petroleum Moves Up In Market Cap Rank, Passing Bristol Myers SquibbIn the latest look at the underlying components of the S&P 500 ordered by largest market capitalization, Marathon Petroleum Corp. (Symbol: MPC) has taken over the #89 spot from Bristol Myers Squibb…NasdaqMPC, BMY
- Will Bristol Myers (BMY) Beat Estimates Again in Its Next Earnings Report?Bristol Myers (BMY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.Nasdaq
- AbbVie's Temab-A Gets Two FDA Breakthrough Therapy Tags in CancerABBV's Temab-A wins two FDA Breakthrough Therapy designations for treating colorectal cancer and non-small cell lung cancer.NasdaqABBV, BMY, CRSP, ACTU
- 2 High-Yield Stocks to Buy in October (Hint: Bristol Myers Squibb Is One)Key PointsBristol Myers Squibb is a pharmaceutical giant with a 100-year history and a 4.2% yield.NasdaqBMY, O
- Bristol-Myers Squibb: Balanced Segment Growth, The Pullback Is An OpportunitySeeking Alpha
- Can Reblozyl Power Bristol Myers' Top-Line Growth Going Forward?Reblozyl's strong growth is helping Bristol Myers offset declining legacy drug sales, with new indications offering further upside.NasdaqBMY, GERN, KROS
- Can Redwire's Microgravity Pharma Work Create New Revenue Streams?RDW expands microgravity applications into pharmaceutical research, creating potential revenue streams through research and licensing.NasdaqRDW, BMY, LLY
- Here's Why Bristol Myers Squibb (BMY) is a Strong Value StockThe Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.Nasdaq
- Bristol-Myers Squibb: Patent Cliff Is Still A ProblemSeeking Alpha
- Zacks.com featured highlights Dollar General, Bristol-Myers Squibb and Equinor ASADollar General, Bristol-Myers Squibb and Equinor ASA have been highlighted in this Screen of The Week article.NasdaqBMY, DG, EQNR
- Relative Strength Alert For Bristol Myers SquibbThe DividendRank formula at Dividend Channel ranks a coverage universe of thousands of dividend stocks, according to a proprietary formula designed to identify those stocks that combine two important…Nasdaq
- BMY Crosses Below Key Moving Average LevelIn trading on Monday, shares of Bristol Myers Squibb Co. (Symbol: BMY) crossed below their 200 day moving average of $59.40, changing hands as low as $58.33 per share. Bristol Myers Squibb Co. shares…Nasdaq
- Monday's ETF with Unusual Volume: TEQIThe T. Rowe Price Equity Income ETF is seeing unusually high volume in afternoon trading Monday, with over 480,000 shares traded versus three month average volume of about 27,000. Shares of TEQI were…NasdaqTEQI, INTC, MDT, MFP
- BMY or ARGX: Which Is the Better Value Stock Right Now?BMY vs. ARGX: Which Stock Is the Better Value Option?NasdaqBMY, ARGX
- Are Investors Undervaluing Bristol Myers Squibb (BMY) Right Now?Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the…Nasdaq
- 3 Stocks With Broker Rating Upgrades Amid Resilient Equity MarketsDollar General, Bristol-Myers and Equinor stand out after broker rating upgrades, backed by projected earnings growth and resilient U.S. equity markets.NasdaqBMY, DG, EQNR
- 3 Dirt Cheap Dividend Stocks Worth Buying in OctoberKey PointsPfizer is getting back on its feet after a difficult post-pandemic stretch.NasdaqPFE, BMY, UNH
- Bristol Myers Squibb Now Trades at Only 9.4X Forward Earnings -- Is This Value Stock a Buy?Key PointsBristol Myers has faced patent cliffs in recent years, and there are more on the horizon.NasdaqBMY, PFE, BNTX
- Notable ETF Inflow Detected - SCHD, COP, ABT, BMYLooking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Schwab US Dividend Equity ETF (Symbol: SCHD) where we have detected…NasdaqSCHD, COP, ABT, BMY
- Agios' Growth Story Hinges on Mitapivat's Commercial ExpansionAGIO's mitapivat is driving growth as Aqvesme gains traction, while an SCD opportunity and pipeline setbacks increase its importance.NasdaqAGIO, NVS, BMY, NVO
- Will Camzyos Growth Keep Driving BMY's Cardiovascular Portfolio?Bristol Myers' Camzyos gains a broader FDA label and strong sales growth, while emerging competitors and pipeline setbacks shape its cardiovascular outlook.NasdaqBMY, CYTK, EWTX
- FDA launches recruitment drive to add members to advisory panelsSeeking Alpha
- VFLO, MVAL: Big ETF OutflowsLooking at units outstanding versus one week prior within the universe of ETFs covered at ETF Channel, the biggest outflow was seen in the VictoryShares Free Cash Flow ETF, where 46,260,000 units…NasdaqVFLO, MVAL, CRM, ACN
- Why Women-Run Companies Deserve a Place in Your PortfolioBMY, HALO, TGT, NEO and ROST stocks show how women-led companies are redefining growth with discipline, agility and results.NasdaqBMY, TGT, ROST, HALO
- XLV, PFE, BMY, DHR: Large Outflows Detected at ETFLooking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the State Street Health Care Select Sector SPDR ETF (Symbol: XLV) where…NasdaqXLV, PFE, BMY, DHR
- BMY vs GILD: Which Biotech Stock Looks More Attractive Now?Bristol Myers' growth portfolio and pipeline advances offer multiple ways to offset legacy-product erosion, while valuation and leverage remain key factors.NasdaqBMY, GILD
- Can Sotyktu's Long-Term PsA Data Boost Bristol Myers' Prospects?Bristol Myers' Sotyktu delivers durable PsA responses for two years, supporting its growth strategy as competition intensifies.NasdaqBMY, AMGN, TAK
- BMY vs. ARGX: Which Stock Is the Better Value Option?BMY vs. ARGX: Which Stock Is the Better Value Option?NasdaqBMY, ARGX
- New FDA Drug Approvals - August 2026(RTTNews) - The U.S. Food and Drug Administration (FDA) granted approval to 13 drugs last month, comprising both new drug approvals and expanded indications for previously approved therapies.NasdaqBMY, BNTX, GILD, JAZZ
- Bristol Myers Squibb's Breakout Is Here: Portfolio Renewal Gaining MomentumSeeking Alpha
- Bristol Myers Squibb: Still Cheap, Despite What The Chart SaysSeeking Alpha
- Bristol Myers Squibb: Buy The Growth Portfolio At A Value PriceSeeking Alpha
- RVMD Secures FDA Win, Gets Nod for Rasonque in Pancreatic CancerRasonque wins FDA approval for pancreatic cancer, giving Revolution Medicines its first marketed product and a commercial foothold.NasdaqRVMD, BMY, SMMT, TNGX
- AstraZeneca, Bristol Myers Squibb To Merge? Let's Consider The Pros And ConsSeeking AlphaBMY, AZN
- After Hours Most Active for Jun 25, 2026 : CPNG, HTZ, NVDA, SLB, AMZN, GOOG, INFY, NKE, BMY, SMCI, AAPL, ACNThe NASDAQ 100 After Hours Indicator is down -116.18 to 29,002.06. The total After hours volume is currently 300,033,236 shares traded.The following are the most active stocks for the after hours…NasdaqCPNG, HTZ, NVDA, SLB
- Ex-Dividend Date Nearing for These 10 Stocks – Week of July 1, 2024NasdaqBBDO, BMY, CMCSA, CSCO